Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prostreat
- Development stage
- Unknown
- Lead developer
- NucleoBio
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Prostreat is an experimental cancer therapeutic developed by NucleoBio Inc. in collaboration with Dr. Olorunseun Ogunwobi at Hunter College of The City University of New York (CUNY) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The drug utilizes synthetic analogs of microRNAs as its active ingredient, representing a novel modality designed to target the ARV7 (Androgen Receptor Variant 7) mutant protein. ARV7 is a common driver of resistance and treatment failure in aggressive prostate cancer. Preclinical studies completed in early 2018 indicated that Prostreat inhibits tumor growth, proliferation, migration, and metastasis with superior efficacy compared to standard-of-care agents such as enzalutamide, abiraterone, and apalutamide. Toxicology studies in animal models have demonstrated a favorable safety profile with no significant toxic side effects.
- Brand names
- Prostreat
Beyond the preview
Go deeper on Prostreat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prostreat.